Prothena/PRTA

$22.24

-4.46%
-
1D1W1MYTD1YMAX

About Prothena

Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

Ticker

PRTA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Gene Kinney

Employees

173

Headquarters

Dublin, Ireland

Prothena Metrics

BasicAdvanced
$1.25B
Market cap
-
P/E ratio
-$2.80
EPS
0.25
Beta
-
Dividend rate
$1.25B
0.25384
$79.65
$21.90
670.9K
11.237
-20.22%
-24.85%
-21.82%
13.687
2.226
2.228
69.5%
-11.88%
374.92%

What the Analysts think about Prothena

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 9 analysts.
200.22% upside
High $94.00
Low $34.00
$22.24
Current price
$66.77
Average price target

Prothena Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-22,466.66% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$300K
-99.65%
Net income
$-67.4M
-407.76%
Profit margin
-22,466.66%
-87,112.63%

Prothena Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 3.56%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.89
-$1.03
$0.38
-$1.26
-
Expected
-$0.94
-$1.00
-$0.32
-$1.22
-$1.20
Surprise
-5.76%
3.42%
-218.01%
3.56%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Prothena stock?

Prothena (PRTA) has a market cap of $1.25B as of April 13, 2024.

What is the P/E ratio for Prothena stock?

The price to earnings (P/E) ratio for Prothena (PRTA) stock is 0 as of April 13, 2024.

Does Prothena stock pay dividends?

No, Prothena (PRTA) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Prothena dividend payment date?

Prothena (PRTA) stock does not pay dividends to its shareholders.

What is the beta indicator for Prothena?

Prothena (PRTA) has a beta rating of 0.25. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Prothena stock price target?

The target price for Prothena (PRTA) stock is $66.77, which is 200.22% above the current price of $22.24. This is an average based on projections from 9 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Prothena stock

Buy or sell Prothena stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing